Dr. Nicolas Noiseux is an eminent cardiac surgeon at CHUM (Centre Hospitalier de l’Université de Montréal), holding several prestigious positions, including Director of the Ex Vivo Perfusion Program and Director of Cardiovascular Research at CHUM. He is also a Full Professor PTG in the Department of Surgery at the Université de Montréal.
In addition to his academic and clinical responsibilities, Dr. Noiseux has been awarded the Senior Clinical Scientist Award by the Fonds de recherche du Québec en Santé (FRQS) and was honored as a Kentucky Colonel in 2018 for his outstanding contributions. He also holds roles in the private sector, serving as Chief Marketing Officer at Targa Biomedical and as a Board Member of the Mira Foundation.
Since becoming a cardiac surgeon in 2002, Dr. Noiseux has been a Full Professor at the Université de Montréal and Director of Cardiovascular Surgery Research at CHUM. His diverse educational background includes a degree in biochemistry, a master’s in molecular biology, and specialization in cardiac surgery (FRCSC). He completed a research fellowship at Harvard Medical School, focusing on regenerative medicine and cellular therapy.
Dr. Noiseux is renowned for initiating pioneering clinical trials such as COMPARE-AMI and IMPACT-CABG, involving intracardiac transplantation of CD133+ stem cells to treat heart failure. He is also co-founder and Chief Medical Officer (CMO) of Targa Biomedical.
His translational research efforts have led to significant advances in organ transplantation, particularly through his ex vivo lung perfusion program, which he launched in 2014 alongside Dr. Pasquale Ferraro. To date, he has performed over 130 procedures, significantly increasing both the quantity and quality of organs available for transplantation.
Research Fields
Dr. Noiseux is an expert in regenerative medicine and cellular therapy, with a particular focus on using stem cells to treat ischemic cardiovascular diseases. He leads groundbreaking clinical studies evaluating the effects of stem cells on ischemic cardiomyopathy and explores the cellular and molecular mechanisms behind these therapies.
His research also extends to ex vivo organ perfusion (lungs, liver, kidneys, and heart), lung transplantation, and preconditioning of stem cells and organs to enhance their function. In addition, he works on developing molecules to increase the therapeutic potential of stem cells and is particularly interested in coronary arteryThe two coronary arteries, the right and the left, form the blood network that supplies the heart with oxygen and nutrients. They are located directly on the surface of the heart and branch into smaller vessels that bypass grafting and complex cardiac surgery.
Expertise
Dr. Noiseux is widely recognized in the following areas:
• Angiogenesis
• Cellular and molecular biology
• Stem cell research and regenerative medicine
• Ex vivo perfusion
• Cellular and genetic therapy
• Cardiac surgery and lung transplantation
With his extensive expertise and numerous contributions, Dr. Noiseux continues to push the boundaries of cardiovascular and regenerative medicine.
